Heart failure devices: Implantable cardioverter-defibrillators and biventricular pacing therapy

Circulation

Volumn 111, Issue 24, 2005, Pages 3327-3335

  Kadish, Alan ^a,c   Mehra, Mandeep ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c NONE   (United States)

Author keywords

Death, sudden; Defibrillation; Electrophysiology; Tachyarrhythmias

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL;

BRUGADA SYNDROME; CARDIAC RESYNCHRONIZATION THERAPY; DEFIBRILLATOR; ELECTRIC BATTERY; HEALTH CARE COST; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART TAMPONADE; HEART VENTRICLE TACHYCARDIA; HEMATOTHORAX; HUMAN; IMPLANT; INFECTION; MICROPROCESSOR; MORBIDITY; MORTALITY; PNEUMOTHORAX; PRIORITY JOURNAL; REVIEW; SHOCK; THORACOTOMY;

CARDIAC PACING, ARTIFICIAL; DEATH, SUDDEN; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; HEART FAILURE, CONGESTIVE; HUMANS; TACHYCARDIA; TREATMENT OUTCOME;

EID: 21044450851     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.481267     Document Type: Review

References (71)

1. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1998;98: 2334-2351.
2. Myerburg RJ, Interian AJ, Mitrani RM, Kesslet KM, Castellanos A. Frequency of sudden cardiac death and profiles of risk. Am J Cardiol. 1997;80:10F-19F.
3. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, Boczor S, Domanski M, Follmann D, Gent M, Roberts RS. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials: AVID, CASH and CIDS studies; Antiarrhythmics vs Implantable Defibrillator study; Cardiac Arrest Study Hamburg; Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21: 2071-2078.
4. Huikuri HV, Castellanso A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001;345:1473-1482.
5. Mirowski M, Mower MM. Transvenous automatic defibrillator as an approach to prevention of sudden death from ventricular fibrillation. Heart Lung. 1973;2:867-869.
6. Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, Langer A, Heilman MS, Kolenik SA, Fischell RE, Weisfeldt ML. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980;303: 322-324.
7. Cannom DS, Prystowsky EN. The evolution of the implantable cardioverter defibrillator. Pacing Clin Electrophysiol. 2004;27:419-431.
8. Wellens HJ, Lau CP, Luderitz B, Akhtar M, Waldo AL, Camm AJ, Timmermans C, Tse HF, Jung W, Jordaens L, Ayers G. Atrioverter: an implantable device for the treatment of atrial fibrillation. Circulation. 1998;98:1651-1656.
9. DiMarco JP. Implantable cardioverter-defibrillators. N Engl J Med. 2003; 349:1836-1847.
10. Lamas G, Lee K, Sweeney M, Silverman R, Leon A, Yee R, Marinchak R, Flaker G, Schron E, Orav E, Hellkamp A, Greer SG, McAnulty J, Ellenbogen K, Ehlert F, Freedman R, Estes NI, Greenspon A, Goldman L. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med. 2002;346:1854-1862.
11. Swerdlow CD, Chen PS, Kass RM, Allard JR, Peter CT. Discrimination of ventricular tachycardia from sinus tachycardia and atrial fibrillation in a tiered-therapy cardioverter-defibrillator. J Am Coll Cardiol. 1994;23: 1342-1355.
12. Rinaldi CA, Simon RD, Baszko A, Bostock J, Elliot D, Bucknall CA, Gill JS. A 17-year experience of inappropriate shock therapy in patients with implantable cardioverter-defibrillators: are we getting any better? Heart. 2004;90:330-331.
13. Leclercq C, Walker S, Linde C, Clementy J, Marshall A, Ritter P, Djiane P, Mabo P, Levy T, Gadler F, Bailleul C, Daubert J. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J. 2002;23:1780-1787.
14. Ukkonen H, Beanlands RS, Burwash IG, de Kemp RA, Nahmias C, Fallen E, Hill MR, Tang AS. Effect of cardiac resynchronization on myocardial efficiency and regional oxidative metabolism. Circulation. 2003;107:28-31.
15. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, Dicarlo L, DeMets D, White BG, DeVries DW, Feldman AM, for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
16. Bradley DJ, Bradley EA, Baughman KL, Berger R, Calkins H, Goodman SN, Kass DA, Powe NR. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA. 2003;289:730-740.
17. Kadish A, Dyer A, Daubert JP, Quigg R, Estes M, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-2158.
18. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
19. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576-1583.
20. Gradaus R, Block M, Brachmann J, Breithardt G, Huber HG, Jung W, Kranig W, Mletzko RU, Schoels W, Seidl K, Senges J, Siebels J, Steinbeck G, Stellbrink C, Andresen D, German ER. Mortality, morbidity, and complications in 3344 patients with implantable cardioverter defibrillators: results fron the German ICD Registry EURID. Pacing Clin Electrophysiol. 2003;26:1511-1518.
21. Kron J, Herre J, Renfroe EG, Rizo-Patron C, Raitt M, Halperin B, Gold M, Goldner B, Wathen M, Wilkoff B, Olarte A, Yao Q. Lead- and device-related complications in the antiarrhythmics versus implantable defibrillators trial. Am Heart J. 2001;141:92-98.
22. Tunis SR. Why Medicare has not established criteria for coverage decisions. N Engl J Med. 2004;350:2196-2198.
23. Sheldon R, Connolly S, Krahn A, Roberts R, Gent M, Gardner M. Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation. 2000;101:1660-1664.
24. Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, Owens DK. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med. 2001;135:870-883.
25. Special report: cost-effectiveness of implantable cardioverter- defibrillators in a MADIT-II population. Technology Evaluation Center Assessment Program. 2004;19:1-2.
26. Winkle RA, Mead RH, Ruder MA, Gaudiani VA, Smith NA, Buch WS, Schmidt P, Shipman T. Long-term outcome with the automatic implantable cardioverter- defibrillator. J Am Coll Cardiol. 1989;13: 1353-1361.
27. Mirowski M, Reid PR, Winkle RA, Mower MM, Watkins L Jr, Stinson EB, Griffith LS, Kallman CH, Weisfeldt ML. Mortality in patients with implanted automatic defibrillators. Ann Intern Med. 1983;98:585-588.
28. Lee DS, Green LD, Liu PP, Dorian P, Newman DM, Grant FC, Tu JV, Alter DA. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol. 2003; 41:1573-1582.
29. Connolly S, Krahn A, Roberts R, Gent M, Gardner M, Connolly SJ. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1660-1664.
30. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748-754.
31. Reynolds MR, Josephson ME. MADIT II (second Multicenter Automated Defibrillator Implantation Trial) debate: risk stratification, costs, and public policy. Circulation. 2003;108:1779-1783.
32. Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am Mean J. 2002;144:440-448.
33. Owens DK, Sanders DG, Harris RA, McDonald KM, Heidenreich PA, Dembitzer A, Hlatky MA. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med. 1997;126:1-12.
34. Oseroff O, Retyk E, Bochoeyer A. Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: Antiarrhythmics Versus Implantable Defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH). Curr Opin Cardiol. 2004;19:26-30.
35. Hallstrom AP, McAnulty JH, Wilkoff BL, Follmann D, Raitt MH, Carlson MD, Gillis AM, Shih HT, Powell JL, Duff H, Halperin BD; Antiarrhythmics Versus Implantable Defibrillator (AVID) Trial Investigators. Patients at lower risk of arrhythmia recurrence: a subgroup in whom implantable defibrillators may not offer benefit. J Am Coll Cardiol. 2001;37:1093-1099.
36. Goldberger JJ, Parker MA, Kadish AH. Over-AVID subgroup analysis. J Am Coll Cardiol. 2001;38:1586-1587.
37. Myerburg RJ, Velez M, Rosenberg DG, Fenster J, Castellanos A. Automatic external defibrillators for prevention of out-of-hospital sudden death: effectiveness of the automatic external defibrillator. J Cardiovasc Electrophysiol. 2003;14:S108-S116.
38. Myerburg RJ, Fenster J, Velez M, Rosenberg D, Lai S, Kurlansky P, Newton S, Knox M, Castellanos A. Impact of community-wide police car deployment of automated external defibrillators on survival from out-of-hospital cardiac arrest. Circulation. 2002;106:1058-1064.
39. Kadish A, Schmaltz S, Calkins H, Morady F. Management of nonsustained ventricular tachycardia guided by electrophysiological testing. Pacing Clin Electrophysiol. 1993;16:1037-1050.
40. Windhagen-Mahnert. Application of noninvasive and invasive tests for risk assessment in patients with ventricular arrhythmias. In: Miller JM, ed. Cardiology Clinic. Philadelphia: WB Saunders Co; 2000:243-263.
41. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337:1569-1575.
42. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo A, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933-1940.
43. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 1999;341:1882-1890.
44. Bardy G. SCD-HeFT: The Sudden Cardiac Death in Heart Failure Trial. Presented as a late-breaking clinical trial at the American College of Cardiology Scientific Sessions, March 8, 2004, detailed results downloaded from http://www.sicr.org/scdheft_results_acc_lbcc.pdf on May 15, 2004.
45. Dorian P, Connolly S, Hohnloser S. DINAMIT: Defibrillator in acute myocardial infarction trial. Presentation at Heart Rhythm 2004 Annual Scientific Sessions, May 22, 2004. Available at http://naspe.box21.com/ W-1168/S5/Start.html. Accessed September 15, 2004.
46. Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, Bitar C, Morady F. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol. 2003;41:1707-1712.
47. Moss AJ. Long QT syndrome. JAMA. 2003;289:2041-2044.
48. Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Giordano U, Bloise R, Giustetto C, De Nardis R, Grillo M, Ronchetti E, Faggiano G, Nastoli J. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002;105:1342-1347.
49. Priori SG, Napolitano C, Memmi M, Columbi B, Drago F, Gasparini M, DeSimone L, Coltorti F, Bloise R, Keegan R, Cruz Filho F, Vignati G, Benatar A, DeLogu A. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69-74.
50. Tavernier R, Gevaert S, De Sutter J, De Clercq A, Rottiers H, Jordaens L, Fonteyne W. Long term results of cardioverter-defibrillator implantation in patients with right ventricular dysplasia and malignant ventricular tachyarrhythmias. Heart. 2001;85:53-56.
51. Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes NA 3rd, Spirito P. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365-373.
52. Nademanee K, Veerakul G, Mower M, Likittanasombat K, Krittayapong R, Bhuripanyo K, Sitthisook S, Chaothawee L, Lai M, Azen S. DEfibrillator versus β-Blockers for Unexplained death in Thailand (DEBUT): a randomized clinical trial. Circulation. 2003;107:2221-2226.
53. Kanzaki H, Bazaz R, Schwartzman D, Dohi K, Sade L, Gorscan J. A mechanism for immediate reduction in mitral regurgitation after cardiac resynchronization therapy: insights from mechanical activation strain mapping. J Am Coll Cardiol. 2004;44:1619-1625.
54. Auricchio A, Abraham W. Cardiac resynchronization therapy: current state of the art: cost versus benefit. Circulation. 2004;109:300-307.
55. Knaapen P, vanCampen L, deCock C, Gotte M, Visser C, Lammertsma A, Visser F. Effects of cardiac resynchronization therapy on myocardial perfusion reserve. Circulation. 2004;110:646-651.
56. Cazeau S, RItter P, Bakdach S. Four chamber pacing in dilated cardiomyopathy. Pacing Clin Electrophysiol. 1994;17:1974-1979.
57. Leclercq C, Cazeau S, Le Breton H, Ritter P, Mabo P, Gras D, Pavin D, Lazarus A, Daubert J. Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure. J Am Coll Cardiol. 1998; 32:1825-1831.
58. Saxon LA, Kerwin W, Cahalan M, Kalman J, Olgin J, Foster E, Schiller N, Shinbane J, Lesh M, Merrick S. Acute effects of intraoperative multisite ventricular pacing on left ventricular function and activation/ contraction sequence in patients with depressed ventricular function. J Cardiovasc Electrophysiol. 1998;9:13-21.
59. Gras D, Leclercq C, Tang AS, Bucknall CA, Luttikhuis H, Kirstein-Pedersen A. Cardiac resynchronization therapy in advanced heart failure. The multicenter InSync clinical study. Eur J Heart Fail. 2002;4:311-320.
60. Abraham WT, Fisher WG, Smith AL, Delurgio D, Leon A, Loh E, Kocovic D, Packer M, Clavell A, Hayes D, Ellestad M, Trupp R, Underwood J, Pickering F, Truex C, McAtee P, Messenger J. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-1853.
61. Guidant Corporation CRM. Summary of safety and effectiveness CONTAK-CD system including CONTAK CD CRT-D pulse generator model 1823, and software application model 2848 (version 3.1). PMA P010012. St Paul, Minn: Guidant Corp; 2002:1-47.
62. Young J, Abraham WT, Smith AL, Leon A, Lieberman R, Wilkoff B, Canby R, Schroeder J, Liem L, Hall S, Wheelan K. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA. 2003; 289:2685-2694.
63. McAlister F, Ezekowitz J, Wiebe N, Rowe B, Spooner C, Crumley E, Hartling L, Klassen T, Abraham WT. Systemic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med. 2004;141:381-390.
64. Mehra M, Greenberg B. Caveat medicus! J Am Coll Cardiol. 2004;43: 1145-1148.
65. Bax J, Bleeker G, Marwick T, Molhoek S, Boersma E, Steendijk P, vander Wall E, Schalij M. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol. 2004;44:1834-1840.
66. Gorscan J, Kanzaki H, Bazaz R, Dohi K, Schwartzman D. Usefulness of echocardiographic tissue synchronization imaging to predict acute response and prognosis after cardiac resynchronization therapy. Am J Cardiol. 2004;1:1178-1181.
67. Bax JJ, Ansalone G, Breithardt O, Derumeaux G, Leclercq C, Schalij M, Sogard P, St John S, Nihoyannopoulos P. Echocardiographic evaluation of cardiac resynchronization therapy: ready for routine clinical use? a critical appraisal. J Am Coll Cardiol. 2004;44:1-9.
68. Abraham W, Young J, Leon A, Adler S, Bank A, Hall S, Lieberman R, Liem L, O'Connell J, Schroeder J, Wheelan K, for the Multicenter InSync ICDII Study Group. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110:2864-2868.
69. Tse HF, Lau CP, Sra JS, Crijns HJ, Edvardsson N, Kacet S, Wyse DG. Atrial fibrillation detection and R-wave synchronization by Metrix implantable atrial defibrillator: implications for long-term efficacy and safety. the Metrix Investigators. Circulation. 1999;99:1446-1451.
70. Israel C, Hugl B, Unterberg C, Lawo T, Kennis I, Hettrick D, Hohnloser S. Pace-termination and pacing for prevention of atrial tachyarrhythmias: results from a multicenter study with an implantable device for atrial therapy. J Cardiovasc Electrophysiol. 2001;12:1121-1128.
71. Israel C, Ehrlich J, Gronefeld G, Klesius A, Lawo T, Lemke B, Hohnloser S. Prevalence, characteristics and clinical implications of regular atrial tachyarrhythmias in patients with atrial fibrillation: insights from a study using a new implantable device. J Am Coll Cardiol. 2001;38:355-363.